Brown named Syapse chief medical officer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Thomas D. Brown was named chief medical officer at Syapse.

Brown joins Syapse from the Swedish Cancer Institute at Providence St. Joseph Health, where he served as executive director of SCI and led the establishment of the SCI Personalized Medicine Program. Brown also served in leadership roles across PSJH, including co-chair of the PSJH Cancer Leadership Council and co-chair of the PSJH Genomics Initiative.

Brown’s clinical and research efforts have been focused on gastrointestinal malignancies, broad developmental therapeutics in oncology, specifically phase I and II clinical trials, and health care policy and global medicine.

Prior to SCI, Brown served as professor of medicine and chief operating officer at the University of Arizona Cancer Center. He also spent a decade at MD Anderson Cancer Center, where he was a professor of medicine, and served as both deputy head and head ad interim of the Division of Cancer Medicine, as well as vice president for international programs.

While on the faculty at Duke University, Brown was one of the founding members of the multi-disciplinary GI cancer program, and of a southeast regional clinical trials consortium. Brown began his career as a faculty member at the University of Texas Health Science Center at San Antonio, working as a member of its phase I program, and serving as an executive officer within the Southwest Oncology Group where he was responsible for coordination of SWOG’s phase II portfolio.

Table of Contents

YOU MAY BE INTERESTED IN

When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced. 
Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login